anastrozole has been researched along with Cancer of Lung in 22 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks." | 9.14 | A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "The efficacy of fulvestrant (Faslodex), a novel oestrogen receptor (ER) antagonist that downregulates the ER and has no known agonist effects, was compared with the aromatase inhibitor anastrozole (Arimidex) for the second-line treatment of advanced breast cancer in postmenopausal women with visceral and non-visceral metastases." | 9.10 | Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. ( Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J, 2003) |
| "A prospective phase III trial comparing anastrozole with tamoxifen as first-line therapy in postmenopausal, hormone-dependent, advanced breast cancer (ABC)." | 9.10 | Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. ( Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E, 2003) |
| " Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases." | 8.82 | A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003) |
| "We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)." | 7.73 | [Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005) |
| "Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer." | 5.35 | [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. ( Hashida, S; Hirano, Y; Iga, K; Inukai, M; Ito, M; Kanaya, Y; Maruyama, S; Shimo, T; Yokoyama, N, 2008) |
| "Anastrozole therapy is a useful treatment for postmenopausal women with ER positive advanced breast cancer." | 5.31 | [Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]. ( Enomoto, K; Kinoshita, T; Nishimura, M; Okamura, Y; Oura, S; Sakurai, T; Yokochi, H, 2002) |
| "Postmenopausal women with advanced breast cancer and > or = 1 visceral (liver or lung) lesion were randomized to anastrozole (1 mg/day orally) or exemestane (25 mg/day orally) for > or = 8 weeks." | 5.14 | A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. ( Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP, 2009) |
| "The efficacy of fulvestrant (Faslodex), a novel oestrogen receptor (ER) antagonist that downregulates the ER and has no known agonist effects, was compared with the aromatase inhibitor anastrozole (Arimidex) for the second-line treatment of advanced breast cancer in postmenopausal women with visceral and non-visceral metastases." | 5.10 | Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. ( Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J, 2003) |
| "A prospective phase III trial comparing anastrozole with tamoxifen as first-line therapy in postmenopausal, hormone-dependent, advanced breast cancer (ABC)." | 5.10 | Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. ( Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E, 2003) |
| " Here we review available efficacy data to address whether or not anastrozole, a non-steroidal aromatase inhibitor (AI), is effective in postmenopausal patients with advanced breast cancer (ABC) and visceral metastases." | 4.82 | A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. ( Howell, A; Robertson, JF; Vergote, I, 2003) |
| "Uterine leiomyosarcoma metastatic to the lungs regressed with the use of the anastrozole aromatase inhibitor." | 3.74 | Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. ( Burnett, AF; Hardman, MP; Roman, JJ; Santin, AD, 2007) |
| "We report three cases with advanced breast cancer were treated with a weekly dose of paclitaxel (TXL)." | 3.73 | [Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. ( Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H, 2005) |
| "The condition is characterized by uterine leiomyomas associated with the development, typically years later, of slow-growing metastatic lesions." | 2.42 | Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. ( Christopoulos, S; Rivera, JA; Small, D; Trifiro, M, 2004) |
| "A solitary pulmonary metastasis from breast cancer with a disease-free interval of longer than 15 years has been quite rarely reported." | 1.40 | [Pulmonary metastasis from breast cancer 38 years after mastectomy; report of a case]. ( Andou, A; Higashi, R; Okutani, D; Yamadori, I, 2014) |
| "Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer." | 1.35 | [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. ( Hashida, S; Hirano, Y; Iga, K; Inukai, M; Ito, M; Kanaya, Y; Maruyama, S; Shimo, T; Yokoyama, N, 2008) |
| "Patients with metastatic endometrial carcinoma may respond to hormonal therapy with progestins." | 1.33 | Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy. ( Hoffman, MA; Khan, A, 2006) |
| "Lung cancer is the most common cancer in the world." | 1.33 | Aromatase inhibitors in human lung cancer therapy. ( Dubinett, SM; Fishbein, MC; Garban, HJ; Goodglick, L; Marquez-Garban, DC; Pietras, RJ; Weinberg, OK, 2005) |
| "Anastrozole therapy is a useful treatment for postmenopausal women with ER positive advanced breast cancer." | 1.31 | [Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report]. ( Enomoto, K; Kinoshita, T; Nishimura, M; Okamura, Y; Oura, S; Sakurai, T; Yokochi, H, 2002) |
| "Anastrozole has excellent antitumor activity in postmenopausal women, but no data exist on its efficacy in men." | 1.31 | Efficacy of anastrozole in male breast cancer. ( Buzdar, AU; Giordano, SH; Hortobagyi, GN; Valero, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (77.27) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mathew, J | 1 |
| Prinsloo, P | 1 |
| Agrawal, A | 1 |
| Gutteridge, E | 1 |
| Marenah, C | 1 |
| Robertson, JF | 2 |
| Cheung, KL | 1 |
| Okutani, D | 1 |
| Andou, A | 1 |
| Yamadori, I | 1 |
| Higashi, R | 1 |
| Moy, B | 1 |
| Specht, MC | 1 |
| Lanuti, M | 1 |
| Rafferty, EA | 1 |
| Lerwill, MF | 1 |
| Nasu, K | 1 |
| Tsuno, A | 1 |
| Takai, N | 1 |
| Narahara, H | 1 |
| Bellone, S | 1 |
| Shah, HR | 1 |
| McKenney, JK | 1 |
| Stone, PJ | 1 |
| Santin, AD | 2 |
| Maruyama, S | 1 |
| Ito, M | 1 |
| Hirano, Y | 1 |
| Shimo, T | 1 |
| Hashida, S | 1 |
| Iga, K | 1 |
| Inukai, M | 1 |
| Kanaya, Y | 1 |
| Yokoyama, N | 1 |
| Campos, SM | 1 |
| Guastalla, JP | 1 |
| Subar, M | 1 |
| Abreu, P | 1 |
| Winer, EP | 1 |
| Cameron, DA | 1 |
| Stabile, LP | 1 |
| Rothstein, ME | 1 |
| Cunningham, DE | 1 |
| Land, SR | 1 |
| Dacic, S | 1 |
| Keohavong, P | 1 |
| Siegfried, JM | 1 |
| Shen, L | 1 |
| Li, Z | 2 |
| Shen, S | 1 |
| Niu, X | 1 |
| Yu, Y | 1 |
| Liao, M | 1 |
| Chen, Z | 1 |
| Lu, S | 1 |
| Sakurai, T | 1 |
| Oura, S | 1 |
| Kinoshita, T | 1 |
| Yokochi, H | 1 |
| Enomoto, K | 1 |
| Nishimura, M | 1 |
| Okamura, Y | 1 |
| Mauriac, L | 1 |
| Pippen, JE | 1 |
| Quaresma Albano, J | 1 |
| Gertler, SZ | 1 |
| Osborne, CK | 1 |
| Milla-Santos, A | 1 |
| Milla, L | 1 |
| Portella, J | 1 |
| Rallo, L | 1 |
| Pons, M | 1 |
| Rodes, E | 1 |
| Casanovas, J | 1 |
| Puig-Gali, M | 1 |
| Howell, A | 1 |
| Vergote, I | 1 |
| Rivera, JA | 1 |
| Christopoulos, S | 1 |
| Small, D | 1 |
| Trifiro, M | 1 |
| Yuasa, H | 1 |
| Katsumine, Y | 1 |
| Uehara, S | 1 |
| Noda, N | 1 |
| Osawa, I | 1 |
| Hoffman, MA | 1 |
| Khan, A | 1 |
| Weinberg, OK | 1 |
| Marquez-Garban, DC | 1 |
| Fishbein, MC | 1 |
| Goodglick, L | 1 |
| Garban, HJ | 1 |
| Dubinett, SM | 1 |
| Pietras, RJ | 1 |
| Rundle, P | 1 |
| Rennie, I | 1 |
| Giordano, SH | 2 |
| Hortobagyi, GN | 2 |
| Hardman, MP | 1 |
| Roman, JJ | 1 |
| Burnett, AF | 1 |
| Alkasi, O | 1 |
| Meinhold-Heerlein, I | 1 |
| Zaki, R | 1 |
| Fasching, P | 1 |
| Maass, N | 1 |
| Jonat, W | 1 |
| Beckmann, MW | 1 |
| Valero, V | 1 |
| Buzdar, AU | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for anastrozole and Cancer of Lung
| Article | Year |
|---|---|
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2003 |
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachial Plexus Neuropath | 2004 |
4 trials available for anastrozole and Cancer of Lung
| Article | Year |
|---|---|
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neo | 2014 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; | 2009 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Fema | 2003 |
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neo | 2003 |
16 other studies available for anastrozole and Cancer of Lung
| Article | Year |
|---|---|
[Pulmonary metastasis from breast cancer 38 years after mastectomy; report of a case].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Fem | 2014 |
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Duc | 2015 |
A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Fallopian Tubes; Female; Humans; Hysterectomy; Leiomyoma; Lung Ne | 2009 |
Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Endometrial Neoplasms; Female; Humans; Immunohist | 2008 |
[A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neopl | 2008 |
Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Carcinogens; Cell Proliferation; Estradiol; Estrogen Rec | 2012 |
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; | 2012 |
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duc | 2002 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2005 |
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; Female; Fulves | 2006 |
Aromatase inhibitors in human lung cancer therapy.
Topics: Anastrozole; Androstenedione; Animals; Aromatase; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lu | 2005 |
Photodynamic therapy for solitary retinal metastasis from breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Combined Modality Therapy | 2006 |
Leuprolide acetate plus aromatase inhibition for male breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2006 |
Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2007 |
Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Surviva | 2009 |
Efficacy of anastrozole in male breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Ne | 2002 |